Search research articles
Contact Us
Filters
Showing results (1-10 of 45) with videos related to
Page
of 5
Sort By:
The Journal of Community and Supportive Oncology
|
May 7, 2016
Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate
David Cella, Susan Li, Tracy Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Reply to A. Addeo and A. Bahl
Howard I Scher, Glenn Heller, Arturo Molina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial
Charles J Ryan, Arturo Molina, Jinhui Li, et al.
European Urology
|
October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy
Peter F A Mulders, Arturo Molina, Michael Marberger, et al.
European Urology
|
July 15, 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301
Bruce Montgomery, Thian Kheoh, Arturo Molina, et al.
The Journal of Urology
|
July 8, 2015
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer
Matthew R Smith, Dana E Rathkopf, Peter F A Mulders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
Charles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Clinical Genitourinary Cancer
|
August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone
Charles J Ryan, Thian Kheoh, Jinhui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2011
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
Charles J Ryan, Shreya Shah, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Stephen Harland, John Staffurth, Arturo Molina, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 45) with videos related to
Sort By:
Page
of 5
The Journal of Community and Supportive Oncology
|
May 7, 2016
Repeated measures analysis of patient-reported outcomes in prostate cancer after abiraterone acetate
David Cella, Susan Li, Tracy Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 25, 2015
Reply to A. Addeo and A. Bahl
Howard I Scher, Glenn Heller, Arturo Molina, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 3, 2013
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial
Charles J Ryan, Arturo Molina, Jinhui Li, et al.
European Urology
|
October 9, 2013
Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy
Peter F A Mulders, Arturo Molina, Michael Marberger, et al.
European Urology
|
July 15, 2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301
Bruce Montgomery, Thian Kheoh, Arturo Molina, et al.
The Journal of Urology
|
July 8, 2015
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer
Matthew R Smith, Dana E Rathkopf, Peter F A Mulders, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
Charles J Ryan, Matthew R Smith, Lawrence Fong, et al.
Clinical Genitourinary Cancer
|
August 29, 2017
Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone
Charles J Ryan, Thian Kheoh, Jinhui Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 3, 2011
Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response
Charles J Ryan, Shreya Shah, Eleni Efstathiou, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 27, 2013
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Stephen Harland, John Staffurth, Arturo Molina, et al.
Page
of 5